Chemical Component Summary

Name ticlopidine
Identifiers 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
Formula C14 H14 Cl N S
Molecular Weight 263.79 g/mol
Type non-polymer
Isomeric SMILES Clc1ccccc1CN1CCc2sccc2C1
InChI InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2

Chemical Details

Formal Charge 0
Atom Count 31
Chiral Atom Count 0
Chiral Atoms
Bond Count 33
Aromatic Bond Count 11

Drug Info: DrugBank

DrugBank ID DB00208   (Stereoisomeric match)
Name Ticlopidine
Groups approved
Description Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
  • Ticlopidina
  • Ticlopidinum
Salts Ticlopidine Hydrochloride
Brand Names
  • Alti-ticlopidine - Tab 250mg
  • Apo-ticlopidine Tablets
  • Dom-ticlopidine
  • Mylan-ticlopidine
  • Nu-ticlopidine 250 mg
Affected Organism Humans and other mammals
Indication Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.
Pharmacology Ticlopidine is a prodrug that is metabolised to an as yet undetermined metabolite that acts as a platelet aggregation inhibitor. Inhibition of platelet aggregation causes a prolongation of bleeding time. In its prodrug form, ticlopidine has no significant in vitro activity at the concentrations attained in vivo.
Mechanism of action The active metabolite of ticlopidine prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of ticlopidine.
Route of administration oral
  • CYP2D6 Inhibitors (Moderate)
  • CYP2B6 Inhibitors (Moderate)
ATC-Code B01AC05
AHFS-Code 20:12.18
CAS number 55142-85-3

Drug Targets

Name Sequence Search Pharmacological Action Actions
P2Y purinoceptor 12 Search yes antagonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682